Daraasadda mustaqbalka ee PCRNNA CTDNA CTDNA Tiknoolajiyada methlation-ka waxay ka furmaysaa marxalad cusub ilaalada MRD ee kansarka mindhicirka

Dhawaan, Jaamac Oncology (haddii 33.012) ay daabacday natiijo cilmi baaris oo muhiim ah (Prof. DNA-da-gaheeyaha iyo khatarta halista ah) ". Daraasaddan ayaa ah daraasadii ugu horreysay ee badan ee adduunka ee lagu dabaqayo dhiiga PCR-ka ee PCDNA MINDEGENES TIXRAACA FARSAMADA ISTICMAALKA ISTICMAALKA ISTICMAALKA ISTICMAALKA ISTICMAALKA ISTICMAALKA ISTICMAALKA ISTICMAALKA ISTICMAALKA ISTICMAALKA ISTICMAALKA ISTICMAALKA ISTICMAALKA. Daraasadda ayaa sidoo kale aad u qiimeysay joornaalka iyo tifaftirayaasheeda, waxaana lagu taxay warqad talooyin muhiim ah oo ku saabsan arrintan, ayuu Juan Ruiz-Bañobre oo ka socda dalka Spain iyo Anjeexoo Professor Anjay Gool Mareykanka ayaa lagu casuumay inay dib u eegaan. Daraasadda ayaa sidoo kale laga soo sheegay GenomeWeb, oo ah hogaamiyaha warbaahinta biomeska ee Mareykanka.

Kansarka mindhicirka (CRC) waa buro caan ah oo caan ah oo ku saabsan marinka caloosha ee Shiinaha. 2020 wakaaladda caalamiga ah ee cilmi baarista 286,000 ayaa la xisaabtamay qiyaastii 1/3 ee adduunka, oo u darantahay sababta shanaad ee ugu badan ee sababa dhimashada kansarka ee Shiinaha. Sababta shanaad ee dhimashada Shiinaha. Waxaa xusid mudan in ka mid ah bukaannada lagu helay, marxaladaha TNM I, II, III iyo IV waa 18.6%, 42.5%, 30.7% iyo 8.2% siday u kala horreeyaan. In ka badan 80% bukaannada ayaa ku jira marxaladaha dhexe iyo gadaal, iyo 44% iyaga ayaa leh isku mar ama heterochroncnon isku mar ah oo ay u kala baxaan metastases beerka, oo ay u horseedaan culays badbaado iyo dhaqaale. Marka loo eego tirakoobka xarunta kansarka qaranka, celceliska korontada ee qiimaha daaweynta kansarka mindhicirka ee Shiinaha ayaa qiyaastii ah 6.9% ilaa 9.2%, iyo kharashaadka caafimaad ee shakhsiyadeed ee bukaannada gudaheeda ay qaadan karaan 60% dakhliga qoyska ee ka mid ah dakhliga qoyska. Bukaanjiifka kansarka ayaa la ildaran cudurka sidoo kale waxaa ku jira cadaadis dhaqaale oo weyn [2].
Sagaashan boqolkiiba sagaashan nabarrada kansarka ee mindhicirka ayaa laga eryi karaa, oo kii hore ee burada, heerka sare ee badbaadada qalliinka ka dib qalliinka qalliinka xagjirka ah, laakiin sicirka guud ee dib-u-noqoshada guud ayaa wali ku dhow 30%. Heerarka badbaadada shanta sano ee badbaadada kansarka mindhicirka ee Shiinuhu waa 90.1%, 72%, 53.8% iyo 10.4% iyo II, III, IV, siday u kala horreeyaan.
Cudurka haraaga haraaga ee ugu yar (MRD) waa sababta ugu weyn ee loo soo celiyo buroka ka dib daaweynta xagjirka ah. Sanadihii la soo dhaafay, tikniyoolajiyadda aasaasiga ah ee MRD ee buskudka adag ayaa si dhakhso leh u sareeya, daraasado culus oo xajiin iyo wax ka qabasha ah ayaa xaqiijinaya in xaaladda ka dib ee MRD-ka postd ay muujineyso halista dib u soo noqoshada kansarka mindhicirka. Tijaabada CTDNNNNA waxay leedahay faa'iidooyinka noqoshada, sahlan, deg deg ah, oo leh marin u muuqda oo muunad ah iyo ka-hortagga dareeraha burooyinka.
Tilmaamaha Mareykanka ee Kansarka Xeryaha ee NCCN iyo Tilmaamaha CSCO ee CSCO ee Kansarka Midabaxda ah ee loo yaqaan 'Mentherapy's ee loo yaqaan Kansarka Khasaaraha ee Dib-u-soo-nooleynta iyo saadaalinta Kansarka ee loo yaqaan' Cheanna ', ee loo saadaalinayo ee lagu garto go'aannada daaweynta ee saadaalinta ee loogu talagalay bukaannada qaba Marxaladda II ama III Kansarka Qaarka. Si kastaba ha noqotee, inta badan daraasadaha jira ayaa diirada saaraya isbedelada CTDNNNA iyadoo lagu saleynayo tikniyoolajiyadda isku-darka sare (NGS), oo leh hanaan waqti dheer, iyo qiimo jaban [3], oo aan hoos udhaceyn oo ka dhex dhaca bukaannada kansarka.
Marka laga hadlayo Marxaladda III Bukaanka Kansarka ee LETDNA, CTDNA STARDNA STARTION CHACTION CHACTION COCTION COUNTION TO $ 10,000 oo loogu talagalay hal booqasho hal booqasho keliya oo u baahan muddo sugitaan ah illaa laba toddobaad. Imtixaanka metrugenelone-ka badan ee daraasaddan, Colonaiiq®, bukaannadu waxay yeelan karaan kormeer firfircoon ctdna ctdna ctdna kharashka qiimaha oo ah wax ku ool ah ugu yaraan laba maalmood.
Sida laga soo xigtay 560,000 kiisas cusub oo kansarka mindhicirka ah Sannad walba, bukaanka caafimaad ee inta badan ee la-socodka firfircoon (markaas) waxay leeyihiin baahida degdegga ah ee isbarbardhiga firfircoon ee kansarka 'MRD' ee firfircoon ee 'MRD' uu gaaro malaayiin dad ah sannad kasta.
Waxaa la arki karaa in natiijooyinka cilmi baarista ay leeyihiin muhiimad muhiim u ah oo wax ku ool ah. Iyada oo loo marayo waxbarasho-guud oo baaxad leh, waxay xaqiijisay in PCR-salka ku-saleysan PCDNA Commogylog tikniyoolajiyadda methloght-ka loo adeegsado saadaalinta ugu dambeysa ee kansarka iyo waxtarka iyo kharashka ku habboon, oo si fiican u oggolaanaya dawada saxda ah si ay uga faa'iideystaan ​​bukaanka kansarka. Daraasaddu waxay ku saleysan tahay Colenaiq®, tijaabada methylation-ka ee hiddaha leh ee loo yaqaan 'Methylation methylation' ee loo yaqaan kansarka mindhicirka ee ay soo saartay Kuny, oo qiimihiisu yahay codsigii caafimaad ee hore ee baarista hore iyo in lagu xaqiijiyo daraasad caafimaad oo dhexe.
Gastroenterology (IFon33.88), joornaalka ugu sareeya caalamiga ah ee ku yaal caloosha caloosha ee Jaamacadda Zudan iyo baaritaanka hore ee kansarka hore iyo ogaanshaha hore ee kansarka mindhicirka, iyo markii hore Waxay sahamisay waxa kale oo ay sidoo kale sahamisaa arjiga suurtagalka ah ee lagu saadaalinayo kor loogu qaado cudurka kansarka mindhicirka.

Si aad u ogeysiiso adeegsiga caafimaad ee ctdna methylation khatarta khatarta ah, ka hagaynta sanntarka luuqada ee I-III qalliinka ka dib qalitaanka, hal bil gudaheed qalliinka ka dib, iyo daweynta ka dib markii la daweeyey dhiigga Tijaabada CTDNA.
Marka hore, waxaa la ogaaday in baaritaanka CTDNNNNNA uu saadaalin karo halista dib u soo noqoshada kansarka kansarka mindhicirka goor hore, labadaba hortooda hortiisa. Bukaan-socodka ka hortagga ee ctdna-togan-ka-fiicani waxay leeyihiin itimaalka sare ee dib-u-soo-noqoshada postificica-ka ee bukaannada ka hortagga ah (22.0%> 4.7%). Tijaabada baaritaanka ee hore ee CTDNNA ee 'CTDNA' ee la saadaaliyo halista soo noqoshada: hal bil kadib markii la taaban lahaa ka dib, bukaannada xagjirka ah ee CTDNNA waxay ahaayeen 17.5 jeer oo ay u badan tahay inay ka soo noqdaan bukaannada taban; Kooxda ayaa sidoo kale ogaatay in isku-darka CTDNNA iyo tijaabada CEA waxyar oo la hagaajiyay waxqabadka ogaanshaha dib u soo-noqoshada (AUC = 0.839) Imtixaanka kaligiis farqiga u dhexeeya isbarbardhiga (ac = 0.839).
Xaraashka kiliinikada ee la isku daro arimaha halista ayaa hadda ah aasaaska ugu weyn ee dadka kale ee ku saabsan bukaanka kansarka, iyo in tiro badan oo bukaanno ah ay wali u baahan yihiin qalabyo sifiican loo daweeyo iyo wada-dhaqanka-ka-hortagga daaweynta ee rugta caafimaadka. Iyada oo ku saleysan tan, kooxdu waxay u kala cadeeyeen bukaanka heerarka III ee Kansarka Luuqada Hoose ee ku saleysan qiimeynta halista caafimaad ee soo-yeelashada (T1-3N1) iyo waqtiga daaweynta ee ugu hooseeya (3/6 bilood). Falanqaynta ayaa lagu ogaaday in bukaannada ku jira koox hoosaadka halista badan ee bukaanka CTDNNA-CLDNNA ay heleen sicirka hoose ee dib-u-soo-nooleynta haddii ay lix bilood ka heleen daaweynta xaashida; Marka loo eego hoosaadyada halista ah ee bukaannada 'CTDNA-' CLDNNE-SEHE, ma jirin farqi weyn oo u dhexeeya wareegga daaweynta ee umusha iyo natiijooyinka bukaanka; In kasta oo Bukaanka CTDNA-taficalku si weyn ay sifiican uga fiicnaayeen bukaannada ku habboon ee CTDNNA iyo xilliga soo noqnoqda ee dib-u-soo-noqoshada (RFS); Marxaladda Marxaladda II II II Kansarka mindhicirka Dhamaan Bukaannada taban ee CTDNNA-ta diidmada ah laba sano gudahood kuma soo noqnoqin laba sano gudahood; Sidaa darteed, is dhexgalka CTDNNNNA oo leh astaamo caafimaad ayaa la filayaa inay sii kordhiso khatarta halista ah iyo dib u soo laabashada saadaalinta.

Jaantus 1. Falanqaynta Plasma Ctdna ee Plom1 si loo ogaado hore ee dib u soo noqoshada kansarka mindhicirka
Natiijooyinka dheeriga ah ee tijaabada dhiigga ee firfircoon ee CTDNA waxay muujisay in halista dib u eegista ay si weyn uga sarreysay tijaabada CTDNA ee ka dib marka loo eego 20 bilood), iyadoo la siinayo suurtogalnimada in la sameeyo (tusaale 3b), oo bixiya suurtagalnimada ogaanshaha cudurka Soo-noqosho iyo faragalin waqtigeeda ah.

Jaantus 2. Falanqaynta CTDNNA ee ku saleysan isku-darka Longudinal-ka si loo ogaado dib u soo noqoshada kansarka mindhicirka

"Daraasad aad u tiro badan oo ka mid ah daraasadaha dawladeed ee tarjumaadda ah ee kansarka mindhicirka ah, gaar ahaan imtixaanka MRDNA-ku saleysan CTDNA waxay muujineysaa awood weyn oo lagu xoojinayo dib-u-soo-noqoshada khatarta ee bukaanka, go'aannada daaweynta ee ku hagaya go'aannada dib-u-eegista hore iyo korjoogteynta hore.

Faa'iidada xulashada DNA-da ee methylation-ka oo ah sumadeeye cusub oo ku saabsan ogaanshaha isbedelka ayaa ah in si toos ah loo isticmaalo baaritaanka dhiiga ee asal ahaan ka soo baxay unugyada caadiga ah, cudurada xunxun, iyo hematoposies.
Daraasaddan iyo daraasadihii kale ee la xiriira ee la xiriira ee CTDNA-ku-saleysan CTDNA ayaa ah kuwa ugu muhiimsan khatarta ugu muhiimsan ee soo-noqoshada Kansarka ugu muhiimsan ee loo yaqaan 'MRD' ee loo yaqaan 'I-III' ee loo yaqaan 'MIDsa'.
Goobtii MRD ayaa si dhakhso leh u kobcinaysa tiro ka mid ah hal-abuurnimo, asbaabo xasaasi ah oo aad u xasaasi ah oo ku saleysan chorenetics (DNA-da metromics) iyo isku-darka (isku-darka loo yaqaan 'theronics'. Waxaan rajeyneynaa in Colonaiq® uu sii wadaa abaabulka daraasadaha caafimaad ee baaxadda leh wuxuuna noqon karaa tilmaame cusub oo ah baaritaanka MRD kaas oo isku daraya gelitaanka, waxqabadka sare iyo kartida iyo si balaaran loo isticmaali karo dhaqanka caafimaad ee joogtada ah. "
Tixraacyo
[1] mo s, Lan, wang d, Han L, zhou S, Wang H, Dou low, Wang Y, Wang H, oo WG ah, Jaamac Oncol. 2023 apr 20.
[2] "Culayska cudurka kansarka mindhicirka ee tirada dadka Shiinaha: Ma isbadalaysay sannadihii ugu dambeeyay? , Joornaalka Shiinaha ee Epidemiology, vol. 41, No. 10, Oktoobar 2020.
[3] Tanazeno-Valenete F, GamBardella v, et al. Bartilmaameedsiga Jiilka soo socda ee kabashada-Tin-ka-wareejinta-burooyinka DNA ee raadraaca cudurka haraaga ugu yar ee kansarka sanka ee maxalliga ah. Ann oncol. Nofeembar 1, 2019; 30 (11): 1804-1812.
[4] Taieb J, André t, auclin E. Galitaanka daweynta xajiska ee kansarka aan caadiga ahayn ee xiidanka, heerarka iyo aragtiyaha cusub. Kansarka daweynta REST. 2019; 75: 1-11.